Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil (Q45353017)

13 December 2017

Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil (English)

1 reference

13 December 2017

1 reference

5

1 reference

13 December 2017

G M N Daleboudt

1

1 reference

13 December 2017

M E J Reinders

2

1 reference

13 December 2017

J den Hartigh

3

1 reference

13 December 2017

T W J Huizinga

4

1 reference

13 December 2017

J W de Fijter

6

1 reference

13 December 2017

S P Berger

7

1 reference

13 December 2017

20 December 2012

1 reference

13 December 2017

1 reference

13 December 2017

22

1 reference

13 December 2017

171-179

1 reference

13 December 2017

2

1 reference

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

13 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Cyclophosphamide: new approaches for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Population pharmacokinetics of mycophenolic acid in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Therapeutic drug monitoring of mycophenolate mofetil in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Pharmacokinetics of mycophenolic acid in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Pharmacokinetics of mycophenolic acid in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312469261

21 January 2018

Identifiers

DOI

10.1177/0961203312469261

1 reference

13 December 2017

1 reference